© European Lead Factory and its partners.
The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n' 115489, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7 / 2007-2013) and EFPIA companies' in kind contribution.
This project has also received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806948: ‘ESCulab: European Screening Centre; Unique Library for Attractive Biology’ and grant agreement No 115489 ‘EUC2LID’. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Medicines for Malaria Venture (MMV).
